Heramed Ltd · ASX:HMD
Heramed — Investor Presentation (July 2023)
45 slides from Heramed's investor presentation, Jul 7, 2023
Slide 1: Leading the Digital Transformation of Maternity Care
For personal use only Leading the Digital Transformation of Maternity Care Investor Presentation | July 2023
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by HeraMED Limited (‘HMC’). Allinformation contained in this presentation (including this notice) (‘information’) is confidential. By receiving the information you are deemed to agree that you will hold the information in strict confidence, > keep it se
Slide 3: HeraMED Overview
HeraMED Overview HeraMED Limited is an ASX listed (ASX:HMD) For personal use only global medical data and technology company leading the digital transformation of maternity care. $20.6m 0.211m Market Capitalisation1 Average daily volume HeraMED offers a proprietary platform that utilises hardware an
Slide 4: HeraMED Highlights
HeraMED Highlights Leading the digital transformation of maternity care @ Maternity care globally has a number of challenges: 1: Rising mortality rates. 2: Shortages of OBGYN's and midwives. 3: A care model unchanged since 1950's. fe) é) HeraCARE is the leading medical grade, clinically validated, e
Slide 5: HeraMED Highlights
HeraMED Highlights Leading the digital transformation of maternity care @ HeraCARrE drives value for all Maternity care globally has a number stakeholders with productivity of challenges: Well defined business gains of 46% for Healthcare 1: Rising mortality rates. model for hospitals, clinics, Provi
Slide 6: HeraMED Highlights
HeraMED Highlights Leading the digital transformation of maternity care @ HeraCARrE drives value for all Maternity care globally has a number stakeholders with productivity of challenges: Well defined business gains of 46% for Healthcare 1: Rising mortality rates. model for hospitals, clinics, Provi
Slide 7: Our Experienced Commercialisation Team
Our Experienced Commercialisation Team Dr. Ron Weinberger Executive Chairman a Keith Koby President, US David Groberman CEO and Co-Founder a Anoushka Gungadin Executive VP ANZ Highly-experienced international business executive with strong scientific background. Former Director, President and CEO of
Slide 8: Maternity Care Challenges
Maternity Care Challenges => 5 25 woz 2 2 Qe 8 15 io) es Os 10 A) os Oss Qa i i) ne 1990 2000 Years tps: anwn-marchotaimesorg/peristats/reports united-states 2010 2015 26 deaths for every 100,000 live births in 2015 U.S.A. (26.4) U.K. (9.2) Portugal (9) Germany (9) France (7.8) Canada (7.3) Netherla
Slide 9: Maternity Care Challenges
Maternity Care Challenges 1990 D> Cc 25 of a 2 Qe 8 15 a S32 Og Yo O38 s Qa — fo) HE 2000 Years itps://iwmw.marchotdimesorg/peristats/reports/urited-states 2010 2015 26 deaths for every 100,000 live births in 2015 U.S.A. (26.4) U.K. (9.2) Portugal (9) Germany (9) France (7.8) Canada (7.3) Netherland
Slide 10: Maternity Care Challenges
Maternity Care Challenges Of the US is a . ‘maternity desert’. Maternity Care Access Access to Maternity Care (1427) For personal HERA @ MED GR sperimurounsyeny sow n-ne ean pa Maternity Desert: No hospital or birth centre and no obstetric provider
Slide 11: Maternity Care Challenges
Maternity Care Challenges Of the US is a ‘maternity desert’. Maternity Care Access low Access to Core (373) For personal HERA @ MED Maternity Care Deserts (112) Moderate Access to Care (223) Access to Maternity Care (1427) https: /monunprorg/2022/10/12/1128335563/maternity-care-deserts-march-ol-dime
Slide 12: Maternity Care Model Challenges
Maternity Care Model Challenges
Slide 13: Maternity Care Model Challenges
Challenges for Doctors and Providers Maternity Care Model Challenges ® Challenges for Expectant Mothers Dramatic shortage of staff and fundamental services Lack of time and attention Episodic, reactive, not connected patient engagement Pregnancy complications and deteriorating delivery outcomes Risk
Slide 14: HeraCARE Value Proposition
HERA @ MED a HeraCARE Value Proposition 14
Slide 15: HeraCARE Value Proposition
ays P Increased Satisfaction Productivity Gains pectin v'} 4 of + Patient-centric collaborative care * Optimise virtual and in-person visits f 5 + Exceptional convenience + Increased revenues a i + Continuous professional support + Reduced cost & + Patient empowerment HeraCARE Value Proposition Empl
Slide 16: For personal use only
For personal use only HERA @ MED 16
Slide 17: HeraBEAT foetal heart rate monitor
HeraBEAT is the leading smart, certified, medical grade foetal heart rate monitor clinically validated for accurate, reliable and safe remote foetal heart rate monitoring. HERA @ MED jj | digital medicine GYNECOLO( Nature.com OBSTETRIC ra 3 7
Slide 18: Traditional Model
a] Traditional Model i OO 8 8 8 68 8 6 88886 8 if a fe 8 8 8 8 7 | For personal use only HERA @ MED 18
Slide 19: Traditional Model vs HeraCARE Model
Traditional Model vs HeraCARE Model a a) srr & 7E 55 8 8 &§ 8 8 6 8 68588 ot For personal u HERA @ MED 19
Slide 20: HeraCARE: New Era of Connected Maternity Care
o HeraCARE: New Era of Connected Maternity Care Gestational Age var 2 4B 4 % 6 WW BW 1% 2 2m 2 2 2% 2% 2% 27 2% 2 390 3 9 33 34 95 36 37 98 98 (40 Pe Gia Dally Recording and Monitoring Throughout fo) (Since 1950) g Ao wbanntansnee [GP poudseordnrasrnerse [GP woannha sei srieb iio a} inne GPonnlgrona
Slide 21: HeraCARE: The New Care Model
HeraCARE: The New Care Model Functionality Full Customisable Video Chat/ Care plans Telehealth Solution Personalised Remote Patient Monitoring Educational Smart Prenatal Content Messaging and (Mayo Clinic) System Postpartum personal use onl For HERA @ MED 21
Slide 22: HeraCARE: The New Care Model
HeraCARE: The New Care Model Functionality Full Customisable Video Chat/ Care plans Telehealth Solution Personalised Remote Patient Monitoring Educational Smart Prenatal Content Messaging and (Mayo Clinic) System Postpartum personal use onl For HERA @ MED a 22
Slide 23: HeraCARE: An end-to end solution
HeraCARE: An end-to end solution Public and Private Clinics Major health system Digital Health Platforms = Cc fo) co) 7) =) i Cc fe) n — o © Government Agencies Insurance Employers Companies HERA @ MED zs
Slide 24: Pregnant mothers endorsing HeraCARE
Pregnant mothers endorsing HeraCARE 87% 4.5 : a “ Re ren : q ¢ , : a Content seen 2 = by 4 R N : 82% 86y, 5; ; ~~ ie Preferred the RPM Experience Contributed to = » Peace of Mind a tH 7 -HERA 8 _MED @ a
Slide 25: Our Commercial Traction and Future Road Map
Ou r Commercial Traction Real world data collected and Future Road Map validated with HeracARE USA Prospect! rospects 2, 600+ Seta Pregnancies Elovu 5,01 90% Snap Inc Satisfaction rate of ‘CLINIC ® = 16,000+ FOND pedi, (ci) e-LOvU FHR Measurements 47,000+ RPM Measurements For personal use only 1500+
Slide 26: Our Commercial Traction and Future Road Map
personal use onl For Our Commercial Traction and Future Road Map Australia Prospects Annual births (potential) Gold Coast UH 5,000 gi JHC Melbourne Mothers JOGG Ponti ott & ss yoo... (ECO HERA ®@ MEDC) femmes, copes: Real world data collected from existing customers and validated with HeraCARE 2,600
Slide 27: Our Commercial Traction and Future Road Map
Our Commercial Traction and Future Road Map HeraMED is building a data repository of unprecented depth and bredth in maternity. + HeraCARE is delivering data and insights for preventative medicine. + Predictive analytics through the use of Al will deliver; 1. Insights to improve maternity care Predi
Slide 28: HeraMED Recommended Pricing Model
HeraMED Recommended >Pricing Model a Per Pregnancy 2 ~US$600 =) OR e One-off HeraBEAT device 8 US$450 ro) + (OL Monthly Saas fee 6 ~US$39-59 ‘Additional connected devices are optional per customer request at extra cost HERA @ MED 28
Slide 29: HeraMED Recommended Pricing Model
HeraMED Recommended >Pricing Model S fo) Per Pregnancy Productivity gains delivered from existing customers () ~US$ 600 Low Risk High Risk 4 Prenatal HeraCARE Traditional HeraCARE Traditional OR Visits 4 14 2 2 oO One-off HeraBEAT device (=z Telehealth % 60% 0% 40% 0% = US$ 450 FOF % 40% 100% 60% 10
Slide 30: HeraCARE drives topline growth for US healthcare providers
HeraCARE drives topline growth for US Increased appointment healthcare providers premeta convenience of virtual appointments > Reimbursement in the US allows healthcare providers to receive : ¢ additional revenue per pregnancy SY) Reimbursement Per Pregnancy Private clinic Reducing revenue a 90489 “
Slide 31: Go to Market Strategies
Go to Market Strategies Customer champions in each market segment = Cc fo) co) 7) =) i Cc fe) n — o © Public hospitals with adopted innovation strategies HERA @ MED Target Healthcare providers with immediate needs Continue to build evidence based validation of HeraCARE Digital Health Platforms seeki
Slide 32: Our Commercialisation Strategy
Our Commercialisation Strategy Foundations in Place Validated data evidence on Robust patent protection © HeraCARE Solution G Leading customers in key verticals Regulatory approved in all contracted in USA & Australia key markets Expanding and progressing commercial pipeline Experienced executive co
Slide 33: Our Commercialisation Strategy
personal use only For Our Commercialisation Strategy HERA @ MED Develop commercial agreements Develop robust integration strategy with leading customers in all that can accommodate customers verticals, establishing commercial in each vertical models for each vertical Develop key strategic Develop st
Slide 34: Successfully Completed: Technological and Clinical Superiority
Successfully Completed: Technological and Clinical Superiority HeraCARE and HeraBEAT redefining home-based maternity care, already proven technological and clinical superiority and have collaboration agreements with leading medical organisations. HERA @ MED 34
Slide 35: Successfully Completed: Technological and Clinical Superiority
Successfully Completed: Technological and Clinical Superiority HeraCARE and HeraBEAT redefining home-based maternity care, already proven technological and clinical superiority and have collaboration agreements with leading medical organisations. HERA @ MED ©) Commercial Pilots and Clinical Trials T
Slide 36: Successfully Completed: Technological and Clinical Superiority
Successfully Completed: G Technological and Clinical Superiority HeraCARE and HeraBEAT redefining home-based maternity care, already proven technological and clinical superiority and have collaboration agreements with leading medical organisations. ©) Commercial Pilots and Clinical Trials Trials and
Slide 37: HeraMED Limited contact and disclaimer
HERA @ MED a HeraMED Limited (ASX:HMD) se only Dr Ron Weinberger Tim Chapman Executive Chairman Investor Relations — —: ron@hera-med.com E: tchapman@claritycap.com.au (OM: +61 406 384 189 M: +61 419 897 062 person Disclaimer Important notice regarding forward looking statements. ‘This document conta
Slide 38: For personal use only
38 Ajuo asn yeuosisad J04
Slide 39: Case Study - Fond employee rewards
Case Study - Fond employee rewards Strategic Partnership with Fond > C+ Improving maternity care with access to HeraMED solution for all Fond clients 7 000+ O -all employees, their partners and up to five family members LU employees benefit ®o . : : with Snap INC Y) * Fond clients include SNAP Inc,
Slide 40: HeraCARE: Employer Direct to Mum Process Flow
HeraCARE: Employer Direct to Mum Process Flow End to end flow to allow Mums access to HeraCARE directly sxand managed by our Partner Refresh Health Employee learns of HeraMed via Fond For personal use onl HERA @ MED Mum purchases HeraCARE solution HeraMeD directly From reviews intake/ HeraMED landin
Slide 41: HeraMED devices donated to Sheba field hospital in Ukraine
For personal use only HeraMED donated devices and professional support for the use of HeraBEAT and HeraCARE in Sheba’s ‘Shining Star’ Field Hospital in Ukraine. The technology was an integral part of providing a connected maternity care solution and gave expecting mums access to medical care where t
Slide 42: Gold Coast Hospital and Health Service - Digital Transformation
Gold Coast Hospital and Health Service - Digital Transformation Gold Coast Hospital and Health Service (GCHHS) is commencing a trial to use HeraCARrE as its new standard of care personal use only HeraCARE will be used for high-risk pregnancies for their Women Newborn and Children Services (WNCS) For
Slide 43: USA Success Story
USA Success Story + For personal use only Noel Pugh, Phd, CEO: e-Lōvu Health is beyond thrilled to partner with HeraMED. A clinically guided digital ecosphere and The HeraCARE platform coupled with the simplicity of the marketplace that helps mothers access health and HeraBEAT smart Fetal HR monitor
Slide 44: Australia Success Story
Australia Success Story + For personal use only +2200 HeraCARE Pregnancies Dr. Cliff Neppe Head of OB at JHC +2200 users Over the past 18 months, we have shown that a Increasing novel, maternally administered fetal heart rate adoption rate monitor (FHRM) has accuracy and safety equivalent to gold-st
Slide 45: Better Outcomes Early Detection of Preeclampsia
Better Outcomes Early Detection of Preeclampsia Case Study - Patient “X” 29 Years Old, First Pregnancy Early Preeclampsia Delivery Indicators Diagnosis For personal use only HeraCARE HeraCARE Alerts Alerts HeraCARE system allowed for identification of preeclampsia that would otherwise have been miss